NDM-1 inhibitor-3 (Compound 89) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor with a Ki of 4 μM.
New Delhi Metallo-β-lactamase-1 (NDM-1), a metallo-β-lactamase (MBL) first discovered at the end of 2008, is now considered as the most clinically relevant target for antibiotic resistance due to its worldwide prevalence[1].
References:
[1]. Caburet J, et al. A fragment-based drug discovery strategy applied to the identification of NDM-1 β-lactamase inhibitors. Eur J Med Chem. 2022 Jul 11;240:114599.
















